For most patients living in the US, turning on the TV and seeing an advertisement for a drug or pharmaceutical product is a common occurrence. In fact, these commercials have become an accepted part of [...]
It is no secret that President Trump is trying to shake up the Healthcare system in the US. After being sworn into office earlier this year, he has taken initial steps to repeal the Affordable [...]
WEP Clinical, a global pharmaceutical and services company, and MendeliKABS Inc., a Canadian pharmaceutical company dedicated to the treatment of rare diseases, announce an exclusive Named Patient agreement to commercialise MDK-Nitisinone (nitisinone), a drug for [...]
Since Britain voted to leave the EU, there has been much speculation on how this decision will affect the pharmaceutical industry and healthcare system within the country. Proponents of Brexit remain optimistic. However, there are [...]
In 2016, Sarepta Therapeutics was given the green light by the FDA for its Duchenne muscular dystrophy (DMD) drug, Exondys 51. It was a huge win for the DMD patient community, as it was the [...]
The 21st Century Cures Act (Cures Act) is going to make it easier for patients to find out important information about accessing investigational new drugs through expanded access. Under this new law, any pharmaceutical company [...]
For many patients in the US, the passing of the 21st Century Cures Act was a great success. This new law will allow Real World Data (RWD) and patient experiences to be to be included [...]
There is still a lot of uncertainty about how the Trump administration will affect the biopharma industry. Some companies are hoping Trump's promise to remove 75-80% of regulation will help them get their drugs to [...]
Upcoming US legislation, known as the 21st Century Cures Act, will incorporate more of the patient experience into drug development. There will be a focus on structured collection of data from patients about the personal [...]